Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P47 versus RoActemra with methotrexate in moderate to severe active rheumatoid arthritis
2022-001066-36Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CT-P47 + methotrexate with RoActemra + methotrexate (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2022; status: completed.
02
Drugs
tocilizumabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-001066-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001066-36.